Previous studies have shown that the overall immunotherapeutic efficacy of driver mutation-positive NSCLC agents, such as EGFR, is unsatisfactory, possibly because of the local immune-negative microenvironment of the tumor after EGFR TKI resistance. Here, EGFR is linked to neoplasm.